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Background:  We aimed to address thresholds of HDL-C and LDL-C to reduce the risk of cardio-cerebrovascular events in Japanese patients 
treated with pitavastatin for dyslipidemia, by conducting the cohort of LIVES Extension in the community.
Methods:  The 6,582 adults with dyslipidemia who had been treated with pitavastatin for the previous 2 years and had agreed to participate in 
this multi-institutional prospective cohort study, were extensively followed-up for the next 3 years. Cardiovascular events, cerebrovascular events and 
sudden death by unknown cause were the endpoints.
Results:  The reduction in LDL-C levels was sustained (-30.3%), while HDL-C levels rose continually on treatment with pitavastatin. In particular, 
mean changes in HDL-C levels were inversely associated with HDL-C levels at baseline; <40mg/dL: 27.0%; 40≤ <45mg/dL: 16.1%; 45≤ <55mg/dL: 
9.3%; 55≤ <65mg/dL: 4.3% and 65mg/dL≤: -2.6%. Cardiovascular events, cerebrovascular events and sudden death were observed in 91, 41 and 
3 patients, respectively. The risk of cardiovascular events was associated with the lowest group of HDL-C levels at baseline (<40mg/dL vs. 65mg/dL≤ 
HR: 3.07, 95%CI 1.47-6.40). HDL-C specific incidence rate ratio (IRR) showed a clear trend that the risk of cardiovascular events increased when 
HDL-C levels were lower than 55mg/dL [<40mg/dL, IRR: 2.55, 95%CI: 1.18-5.52, 40≤ <45mg/dL, IRR: 2.83, 95%CI 1.34-5.99, 45≤ <55mg/dL, IRR: 
2.08, 95%CI 1.06-4.10, 55≤ <65mg/dL, IRR: 1.59, 95%CI 0.77-3.27, 65mg/dL≤, IRR: 1, adjusted by multi-variate analysis. Moreover, none of these 
cholesterol markers showed significant associations with cerebrovascular events.
Conclusions: Our interim data suggest that, in Japanese community-based clinical practice, HDL-C levels in treatment may be predictive of 
residual cardiovascular risk among patients treated with pitavastatin therapy after reducing LDL-C levels.
